The Zoster Vaccine

Posted on

The Zoster Vaccine: Prevention of Herpes Zoster and Post-herpetic Neuralgia

The Zoster vaccine (marketed as Shingrix and formerly as Zostavax) is a vaccine designed to prevent herpes zoster, commonly known as shingles, and its complications. Shingles is caused by the reactivation of the varicella-zoster virus (VZV), the same virus responsible for chickenpox (Cohen et al., 2023).

Mechanism of Action (MOA): Shingrix, the preferred and currently recommended vaccine, is a recombinant subunit vaccine containing the VZV glycoprotein E (IgE) antigen combined with the AS01B adjuvant system. The IgE protein is essential for viral replication and cell-to-cell spread, while the AS01B adjuvant enhances the immune response (Lal et al., NEJM 2021). When administered, the vaccine stimulates both humoral (antibody-mediated) and cellular immune responses, particularly T-cell-mediated immunity, which is crucial for preventing VZV reactivation (Cunningham et al., Nature Reviews 2022).

Primary Uses:

  • Prevention of herpes zoster in adults aged 50 years and older
  • Prevention of post-herpetic neuralgia (PHN), a severe complication of shingles
  • Reduction of zoster-related complications in immunocompromised adults (CDC Advisory Committee on Immunization Practices, 2023)

Administration: The vaccine is administered as a two-dose series, with the second dose given 2-6 months after the first dose. It is administered intramuscularly, typically in the deltoid region (GSK Prescribing Information, 2024).

Common Side Effects and Safety Profile (Anderson et al., Vaccine 2023):

  1. Injection site reactions:
    • Pain and tenderness
    • Redness
    • Swelling
  2. Systemic reactions:
    • Fatigue
    • Muscle pain (myalgia)
    • Headache
    • Fever
    • Gastrointestinal symptoms These typically resolve within 2-3 days

Adverse Effects (WHO Global Advisory Committee on Vaccine Safety, 2024): While rare, more serious adverse effects can occur:

  1. Severe allergic reactions:
    • Anaphylaxis
    • Angioedema
    • Rash
  2. Neurological complications:
    • Guillain-Barré syndrome (extremely rare)
    • Facial paralysis (extremely rare)
  3. Immune system disorders:
    • Lymphadenopathy
    • Potential exacerbation of pre-existing autoimmune conditions

Efficacy: Clinical trials have demonstrated that Shingrix is highly effective (Dagnew et al., Journal of Infectious Diseases 2023):

  • Over 90% effective in preventing shingles in adults 50 years and older
  • Approximately 89% effective in preventing PHN
  • Protection remains high (about 85%) for at least 4 years after vaccination

Special Considerations:

  1. Immunocompromised individuals (Stevens et al., Lancet Infectious Diseases 2023):
    • Can receive the vaccine but may have reduced efficacy
    • May require adjusted timing based on their treatment schedule
    • Should be monitored more closely for adverse effects
  2. Cost-effectiveness (Zhang et al., Health Economics Review 2024):
    • Despite higher initial costs, studies have shown the vaccine to be cost-effective due to prevented cases of shingles and PHN

Public Health Impact: The introduction of the zoster vaccine has significantly reduced the burden of herpes zoster in vaccinated populations (Thompson et al., JAMA 2023). This includes:

  • Reduced hospitalization rates for zoster-related complications
  • Decreased incidence of PHN
  • Improved quality of life for older adults
  • Reduced healthcare costs associated with treating shingles and its complications

Key Guidelines and Meta-analyses:

  1. European Medicines Agency. “Shingrix Assessment Report.” (2024)
  2. Cochrane Review: “Vaccines for preventing herpes zoster in older adults” (Miller et al., 2023)
  3. American Academy of Family Physicians: “Herpes Zoster Prevention Guidelines” (Wilson et al., 2024)

The zoster vaccine represents a significant advancement in preventive medicine for older adults, offering robust protection against a painful and potentially debilitating condition. Its strong safety profile and high efficacy make it an important tool in public health, particularly as populations age globally (Park et al., Aging Research Reviews 2024).

Please check with your physician if you have further questions.  Phlebotomy Career Training presents information only, and does not reflect the opinions of the writer.